BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chang JY, Cheon JH. Thiopurine Therapy in Patients With Inflammatory Bowel Disease: A Focus on Metabolism and Pharmacogenetics. Dig Dis Sci 2019;64:2395-403. [PMID: 31290039 DOI: 10.1007/s10620-019-05720-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Harmand PO, Solassol J. Thiopurine Drugs in the Treatment of Ulcerative Colitis: Identification of a Novel Deleterious Mutation in TPMT. Genes (Basel) 2020;11:E1212. [PMID: 33081236 DOI: 10.3390/genes11101212] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
2 Andoh A, Kawahara M, Imai T, Tatsumi G, Inatomi O, Kakuta Y. Thiopurine pharmacogenomics and pregnancy in inflammatory bowel disease. J Gastroenterol 2021. [PMID: 34287682 DOI: 10.1007/s00535-021-01805-z] [Reference Citation Analysis]
3 Bąk-Drabik K, Adamczyk P, Duda-Wrońska J, Dąbrowska-Piechota D, Jarzumbek A, Kwiecień J. Usefulness of Measuring Thiopurine Metabolites in Children with Inflammatory Bowel Disease and Autoimmunological Hepatitis, Treated with Azathioprine. Gastroenterol Res Pract 2021;2021:9970019. [PMID: 34239556 DOI: 10.1155/2021/9970019] [Reference Citation Analysis]
4 Tanaka Y, Saito Y. Importance of NUDT15 Polymorphisms in Thiopurine Treatments. J Pers Med 2021;11:778. [PMID: 34442422 DOI: 10.3390/jpm11080778] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Cheon JH. Advances in Management of Intestinal Behçet’s Disease: A Perspective From Gastroenterologists. J Rheum Dis 2021;28:4-16. [DOI: 10.4078/jrd.2021.28.1.4] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Chang JY, Cheon JH. Pharmacogenetics-based personalized treatment in patients with inflammatory bowel disease: A review. Precis Future Med 2021;5:151-63. [DOI: 10.23838/pfm.2021.00128] [Reference Citation Analysis]
7 Roselli J, Innocenti T, Lynch EN, Parisio L, Macrì G, Milla M, Mello T, Galli A, Milani S, Tarocchi M. Increased Risk of Liver Cirrhosis during Azathioprine Therapy for Crohn's Disease. Case Rep Gastrointest Med 2020;2020:6726384. [PMID: 32082651 DOI: 10.1155/2020/6726384] [Reference Citation Analysis]
8 Kim ES, Choi S, Choi SY, Park JH, Choe BH, Lee SY, Kim MJ, Choe YH, Kang B. NUDT15 intermediate metabolisers are associated with lower loss of response in paediatric Crohn's disease patients treated by combination treatment with infliximab and azathioprine. Aliment Pharmacol Ther 2022. [PMID: 35032047 DOI: 10.1111/apt.16769] [Reference Citation Analysis]